Pliant Therapeutics (STU:9PT) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:9PT Pliant Therapeutics Inc STU:9PT
34 GF Score
Price €0.99
GF Value €0.38
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Pliant Therapeutics Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

STU:9PT
34GF Score
Pliant Therapeutics Inc STU:9PT
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Pliant Therapeutics (STU:9PT) Overvalued in 2026?

Based on GuruFocus' analysis, Pliant Therapeutics stock appears to be overvalued. The current stock price of €0.99 is trading 161.1% above its estimated GF Value™ of €0.38. GuruFocus considers Pliant Therapeutics to be Significantly Overvalued.

Key valuation signals for STU:9PT:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: €0.38 vs. price of €0.99 (161.1% above fair value)
  • GF Score™: 34/100 with 3 warning signs

No single metric tells the full story. See the STU:9PT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Pliant Therapeutics Business Description

Other Exchanges PLRX:USA
Address 331 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.
34GF Score

Get the complete analysis for STU:9PT

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.99
Price
€0.38
GF Value